指南与共识头颈部肿瘤放疗消化道肿瘤放疗胸部肿瘤放疗

美国癌症多模式治疗指南不依从性研究

Nonadherence to Multimodality Cancer Treatment Guidelines in the United States.
指南 / 共识 · Adv Radiat Oncol · 2022-03-08

该研究从美国国家癌症数据库中选取五种指南明确界定多模式治疗(手术、化疗和放疗)的癌症患者,分析未接受指南一致治疗的患者特征及相关因素。共纳入178,005例患者,其中91%接受指南一致治疗,9%未接受;宫颈癌未接受比例最高(21%),鼻咽癌最低(3%)。年龄较大、合并症及低容量机构评估的患者更不可能接受指南一致治疗。

要点

  • 该队列中近十分之一患者未接受适当的多模式癌症治疗。
  • 宫颈癌患者未接受指南一致治疗的比例为21%,居五种癌症之首。
  • 年龄较大、有合并症及在低容量机构评估的患者接受指南一致治疗的可能性更低。

核心结论

  • 该队列中近十分之一患者未接受适当的多模式癌症治疗。
  • 基于原发肿瘤部位、年龄、合并症和报告机构,接受指南一致治疗存在显著差异。

研究设计与样本

  • 从美国国家癌症数据库选取五种指南明确界定多模式治疗(手术、化疗和放疗)的癌症:非转移性肛管癌、局部晚期宫颈癌、非转移性鼻咽癌、局部晚期直肠癌和局部晚期非小细胞肺癌。
  • 采用多变量逻辑回归调整常见混杂变量,计算接受与未接受指南一致治疗的比值比(95%置信区间)。
  • 共纳入178,005例患者:肛管癌32,214例、直肠癌54,485例、宫颈癌13,179例、鼻咽癌5,061例、肺癌73,066例。

主要发现

  • 总体162,514例(91%)接受指南一致治疗,15,491例(9%)未接受。
  • 宫颈癌患者21%未接受指南一致治疗,直肠癌10%,肺癌7%,肛管癌5%,鼻咽癌3%。
  • 一般而言,年龄较大、有合并症及在低容量机构评估的患者接受指南一致治疗的可能性更低(比值比>1,P<.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our purpose was to identify patients with cancer who do not receive guideline-concordant multimodality treatment and to identify factors that are associated with nonreceipt of guideline-concordant multimodality treatment. METHODS AND MATERIALS: Five cancers for which the multimodal guideline-concordant treatment (with surgery, chemotherapy, and radiation therapy) is clearly defined in national guidelines were selected from the National Cancer Database: (1) nonmetastatic anal cancer, (2) locally advanced cervical cancer, (3) nonmetastatic nasopharynx cancer, (4) locally advanced rectal cancer, and (5) locally advanced non-small cell lung cancer. Multivariable logistic regression was used to determine the odds ratios (with 95% confidence intervals) of receiving the guideline-concordant treatment versus not, adjusting for common confounding variables. RESULTS: 178,005 patients with cancer were included: 32,214 anal, 54,485 rectal, 13,179 cervical, 5061 nasopharyngeal, and 73,066 lung. Overall, 162,514 (91%) received guideline-concordant treatment and 15,491 (9%) did not. Twenty-one percent of patients with cervical cancer, 10% of patients with rectal cancer, 7% of patients with lung cancer, 5% of patients with anal cancer, and 3% of patients with nasopharynx cancer did not receive guideline-concordant treatment. In general, patients who were older, with comorbid conditions, and who were evaluated at low-volume facilities (odds ratios > 1 with P < .05) were less likely to receive guideline-concordant treatment. CONCLUSIONS: Nearly 1 in 10 patients in this cohort are not receiving appropriate multimodal cancer therapy. There appear to be significant disparities in receipt of guideline-concordant treatment based on primary tumor site, age, comorbidities, and reporting facility.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Tchelebi LT, Shen B, Wang M, et al. Nonadherence to Multimodality Cancer Treatment Guidelines in the United States. Adv Radiat Oncol. 2022. PMID: 35469182. doi:10.1016/j.adro.2022.100938

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。